A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients
A Phase 2a, Randomized, Open-Label, Single-Site Study to Evaluate the Pharmacodynamic Effects and Safety of RDEA3170 Administered in Combination With Febuxostat Compared to RDEA3170 Administered Alone and Febuxostat Administered Alone, Respectively in Japanese Adult Male Subjects With Gout or Asymptomatic Hyperuricemia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Fukuoka-shi, Japan
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Screening serum uric acid level ≥ 8 mg/dL;
- Body weight ≥ 50 kg and a body mass index (BMI) ≥ 18 and ≤ 40 kg/m2;
- Free of any clinically significant disease or medical condition, per the Investigator's judgment.
Exclusion Criteria:
- History or suspicion of kidney stones;
- Diagnosis of benign prostatic hypertrophy (BPH) or neurogenic bladder or evidence of BPH/neurogenic bladder such as thin urinary stream or difficulty in urination;
- An estimated creatinine clearance < 60 mL/min calculated by the Cockcroft-Gault formula;
- QTcF interval (QT interval corrected for heart rate using Fridericia's formula) > 450 msec at Screening;
- Receiving strong or moderate Cytochrome P450 (CYP) 3A inhibitors or p-glycoprotein inhibitors, or digoxin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cohort 1
The half of patients randomized to this cohort will be dosed in the order of Febuxostat 10mg, RDEA3170 2.5 mg + Febuxostat 10mg, RDEA3170 2.5 mg + Febuxostat 20mg, and Febuxostat 20mg.
The other half will be dosed in the reverse order.
|
Oral Treatment
Oral Treatment
|
|
Experimental: Cohort 2
The half of patients randomized to this cohort will be dosed in the order of Febuxostat 10mg, RDEA3170 5 mg + Febuxostat 10mg, RDEA3170 5 mg + Febuxostat 20mg, and Febuxostat 20mg.
The other half will be dosed in the reverse order.
|
Oral Treatment
Oral Treatment
|
|
Experimental: Cohort 3
The half of patients randomized to this cohort will be dosed in the order of Febuxostat 20mg, RDEA3170 5 mg + Febuxostat 20mg, RDEA3170 5 mg + Febuxostat 40mg, and Febuxostat 40mg.
The other half will be dosed in the reverse order.
|
Oral Treatment
Oral Treatment
|
|
Experimental: Cohort 4
The half of patients randomized to this cohort will be dosed in the order of Febuxostat 20mg, RDEA3170 10 mg + Febuxostat 20mg, RDEA3170 10 mg + Febuxostat 40mg, and Febuxostat 40mg.
The other half will be dosed in the reverse order.
|
Oral Treatment
Oral Treatment
|
|
Experimental: Cohort 5
RDEA3170 2.5mg, RDEA3170 5mg, RDEA3170 10mg, RDEA3170 15mg
|
Oral Treatment
|
|
Experimental: Cohort 6
The half of patients randomized to this cohort will be dosed in the order of Benzbromarone 50 mg, Febuxostat 10mg+RDEA3170 2.5 mg, then Febuxostat 20mg+RDEA3170 5 mg.
The other half will be dosed in the order of Febuxostat 10mg+RDEA3170 2.5 mg, Febuxostat 20mg+RDEA3170 5 mg, then Benzbromarone 50mg.
|
Oral Treatment
Oral Treatment
Oral Treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Serum uric acid level
Time Frame: baseline and day 7 on each treatment
|
% change per treatment will be compared.
|
baseline and day 7 on each treatment
|
|
Change in Urinary excretion of uric acid
Time Frame: baseline and day 7 on each treatment
|
Timed urinary uric acid excretion per treatment will be compared
|
baseline and day 7 on each treatment
|
|
Renal clearance of uric acid
Time Frame: baseline and day 7 on each treatment
|
Renal clearance of uric acid will be calculated.
|
baseline and day 7 on each treatment
|
|
Fractional excretion of uric acid
Time Frame: baseline and day 7 on each treatment
|
Fractional excretion and renal clearance of uric acid will be calculated.
|
baseline and day 7 on each treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum plasma concentration (Cmax)
Time Frame: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 , 24 hours post-dose on each treatment
|
To assess multiple-dose PK of RDEA3170 and febuxostat alone or in combination treatment.
|
0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 , 24 hours post-dose on each treatment
|
|
Time to reach maximum concentration (tmax)
Time Frame: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 , 24 hours post-dose on each treatment
|
To assess multiple-dose PK of RDEA3170 and febuxostat alone or in combination treatment.
|
0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 , 24 hours post-dose on each treatment
|
|
Area under the concentration-time curve (AUC)
Time Frame: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 , 24 hours post-dose on each treatment
|
To assess multiple-dose PK of RDEA3170 and febuxostat alone or in combination treatment.
|
0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 , 24 hours post-dose on each treatment
|
|
Half life (t1/2)
Time Frame: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 , 24 hours post-dose on each treatment
|
To assess multiple-dose PK of RDEA3170 and febuxostat alone or in combination treatment.
|
0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 , 24 hours post-dose on each treatment
|
|
Incidence of adverse events
Time Frame: Day 1 and Day 7 on each treatment
|
To evaluate the safety and tolerability of febuxostat alone, RDEA3170 alone and RDEA3170 administered in combination of febuxostat and febuxostat in combination of RDEA3170
|
Day 1 and Day 7 on each treatment
|
|
Changes in hematology, serum chemistry, coagulation, electrocardiogram and urinalysis parameters
Time Frame: Day 1 and Day 8 on each treatment
|
To evaluate the safety and tolerability of febuxostat alone, RDEA3170 alone and RDEA3170 administered in combination of febuxostat and febuxostat in combination of RDEA3170
|
Day 1 and Day 8 on each treatment
|
|
Changes in vital signs and physical examination findings
Time Frame: Day 1 and Day 8 on each treatment
|
To evaluate the safety and tolerability of febuxostat alone, RDEA3170 alone and RDEA3170 administered in combination of febuxostat and febuxostat in combination of RDEA3170
|
Day 1 and Day 8 on each treatment
|
|
Incidence of adverse events
Time Frame: Day 42 of the study as follow up
|
To evaluate the safety and tolerability of febuxostat alone, RDEA3170 alone and RDEA3170 administered in combination of febuxostat and febuxostat in combination of RDEA3170
|
Day 42 of the study as follow up
|
|
Changes in hematology, serum chemistry, coagulation, electrocardiogram and urinalysis parameters
Time Frame: Day 42 of the study as follow up
|
To evaluate the safety and tolerability of febuxostat alone, RDEA3170 alone and RDEA3170 administered in combination of febuxostat and febuxostat in combination of RDEA3170
|
Day 42 of the study as follow up
|
|
Changes in vital signs and physical examination findings
Time Frame: Day 42 of the study as follow up
|
To evaluate the safety and tolerability of febuxostat alone, RDEA3170 alone and RDEA3170 administered in combination of febuxostat and febuxostat in combination of RDEA3170
|
Day 42 of the study as follow up
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Urinary pH
Time Frame: baseline and day 7 on each treatment
|
To evaluate the relationship between the doses of uralyt and urinary pH under the administration of RDEA3170.
|
baseline and day 7 on each treatment
|
|
Deoxyribonucleic acid polymorphism
Time Frame: Day 1 of the study as randomization
|
To collect and store deoxyribonucleic acid (DNA) for future exploratory research.
|
Day 1 of the study as randomization
|
|
Change in Serum uric acid level
Time Frame: Baseline and day 7 on each treatment for cohort 6
|
% change per treatment will be compared.
|
Baseline and day 7 on each treatment for cohort 6
|
|
Change in Urinary excretion of uric acid
Time Frame: Baseline and day 7 on each treatment for cohort 6
|
Timed urinary uric acid excretion per treatment will be compared.
|
Baseline and day 7 on each treatment for cohort 6
|
|
Renal clearance of uric acid
Time Frame: Baseline and day 7 on each treatment for cohort 6
|
Renal clearance of uric acid will be calculated.
|
Baseline and day 7 on each treatment for cohort 6
|
|
Fractional excretion of uric acid
Time Frame: Baseline and day 7 on each treatment for cohort 6
|
Fractional excretion and renal clearance of uric acid will be calculated.
|
Baseline and day 7 on each treatment for cohort 6
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Rekic D, Johansson S, Leander J. Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of Bodyweight. Clin Pharmacokinet. 2021 Mar;60(3):319-328. doi: 10.1007/s40262-020-00943-6. Epub 2020 Sep 19.
- Shiramoto M, Liu S, Shen Z, Yan X, Yamamoto A, Gillen M, Ito Y, Hall J. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study. Rheumatology (Oxford). 2018 Sep 1;57(9):1602-1610. doi: 10.1093/rheumatology/key100.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Genetic Diseases, Inborn
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Metabolism, Inborn Errors
- Crystal Arthropathies
- Purine-Pyrimidine Metabolism, Inborn Errors
- Hyperuricemia
- Gout
- Antirheumatic Agents
- Gout Suppressants
- Renal Agents
- Uricosuric Agents
- Febuxostat
- Verinurad
- Benzbromarone
Other Study ID Numbers
Other Study ID Numbers
- D5491L00001
- RDEA3170-205 (Other Identifier: Ardea Biosciences, Inc.)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.